To ask the Scottish Executive what cost benefit analysis has been undertaken, in partnership with the NHS in England and Wales where appropriate, into the use of newer, safer, more effective medicines rather than older, less expensive drugs which may have a poorer safety profile and a lower level of patient compliance.